Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) Net Margin (2020 - 2024)

Fulcrum Therapeutics (FULC) has 5 years of Net Margin data on record, last reported at 69.26% in Q2 2024.

  • On a quarterly basis, Net Margin rose 277187.0% to 69.26% in Q2 2024 year-over-year; TTM through Jun 2025 was 91.52%, a 6673.0% decrease, with the full-year FY2024 number at 12.16%, up 345790.0% from a year prior.
  • Net Margin reached 69.26% in Q2 2024 per FULC's latest filing, up from 2842.25% in the prior quarter.
  • Over the last five years, Net Margin for FULC hit a ceiling of 69.26% in Q2 2024 and a floor of 8399.66% in Q1 2023.
  • A 5-year average of 1885.27% and a median of 1026.08% in 2020 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: tumbled -739935bps in 2023, then skyrocketed 277187bps in 2024.
  • Tracing FULC's Net Margin over 5 years: stood at 419.41% in 2020, then decreased by -11bps to 464.29% in 2021, then plummeted by -722bps to 3815.33% in 2022, then rose by 26bps to 2842.25% in 2023, then soared by 102bps to 69.26% in 2024.
  • Business Quant data shows Net Margin for FULC at 69.26% in Q2 2024, 2842.25% in Q4 2023, and 3164.3% in Q3 2023.